{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:30:09Z","timestamp":1761129009684,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.rdc.2012.08.005","type":"journal-article","created":{"date-parts":[[2012,9,15]],"date-time":"2012-09-15T09:15:33Z","timestamp":1347700533000},"page":"601-611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Therapeutic Controversies in Spondyloarthritis"],"prefix":"10.1016","volume":"38","author":[{"given":"Denis","family":"Poddubnyy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9sir\u00e9e van der","family":"Heijde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rdc.2012.08.005_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.005_bib2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.005_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ard.2003.019174","article-title":"Six months open label trial of leflunomide in active ankylosing spondylitis","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.005_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.005_bib5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/ard.2007.080077","article-title":"Dissemination and evaluation of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists","volume":"67","author":"Gossec","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.005_bib6","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/ard.2011.151167","article-title":"Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain?","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.005_bib7","first-page":"10","article-title":"Are classification criteria for spondylarthropathy useful as diagnostic criteria?","volume":"62","author":"Amor","year":"1995","journal-title":"Rev Rhum Engl Ed"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.005_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","article-title":"Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.005_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/rheumatology\/38.3.235","article-title":"Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial","volume":"38","author":"Dougados","year":"1999","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.005_bib10","first-page":"1805","article-title":"Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis","volume":"33","author":"Barkhuizen","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.005_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.2007.075309","article-title":"Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study","volume":"67","author":"Sieper","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.005_bib12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","article-title":"Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis\u2013a population-based survey","volume":"25","author":"Zochling","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.005_bib13","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/ard.2004.029611","article-title":"Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis","volume":"64","author":"Gossec","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2012.08.005_bib14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/annrheumdis-2012-eular.2239","article-title":"Double-blind, placebo-controlled, 28-week trial of efficacy and safety of infliximab plus naproxen vs naproxen alone in patients with early, active axial spondyloarthritis treated with a submaximal dose of NSAIDs: preliminary results of INFAST Part I","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.005_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2010.133488","article-title":"ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.005_bib16","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/ard.2009.120139","article-title":"Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis","volume":"69","author":"Poddubnyy","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.005_bib17","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/ard.2010.145995","article-title":"Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis","volume":"70","author":"Poddubnyy","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.005_bib18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","article-title":"Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis","volume":"64","author":"Poddubnyy","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.005_bib19","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1136\/ard.2008.092213","article-title":"MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib","volume":"68","author":"Jarrett","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.005_bib20","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/ard.2004.029728","article-title":"Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?","volume":"64","author":"Wanders","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.005_bib21","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/ard.2009.124206","article-title":"Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis","volume":"69","author":"Machado","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.005_bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.2008.091793","article-title":"Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine","volume":"68","author":"Landewe","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.005_bib23","first-page":"60","article-title":"Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone","volume":"5","author":"Boersma","year":"1976","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.005_bib24","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.005_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.2004.020503","article-title":"Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system","volume":"64","author":"Creemers","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.005_bib26","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German spondyloarthritis inception cohort","volume":"71","author":"Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.005_bib27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.005_bib28","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.005_bib29","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.005_bib30","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.005_bib31","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.tem.2009.12.004","article-title":"Prostaglandins in bone: bad cop, good cop?","volume":"21","author":"Blackwell","year":"2010","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.005_bib32","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1172\/JCI0215681","article-title":"Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair","volume":"109","author":"Zhang","year":"2002","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.005_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/joca.1998.0230","article-title":"Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis and cartilage \/ OARS","volume":"7","author":"Raisz","year":"1999","journal-title":"Osteoarthritis Cartilage"},{"issue":"Suppl 5","key":"10.1016\/j.rdc.2012.08.005_bib34","doi-asserted-by":"crossref","first-page":"s3","DOI":"10.1097\/00124743-199810001-00002","article-title":"Differential inhibition of cyclooxygenase isoforms: an explanation of the action of NSAIDs","volume":"4","author":"Vane","year":"1998","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.005_bib35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"issue":"9560","key":"10.1016\/j.rdc.2012.08.005_bib36","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0140-6736(07)60234-7","article-title":"Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison","volume":"369","author":"Laine","year":"2007","journal-title":"Lancet"},{"issue":"9435","key":"10.1016\/j.rdc.2012.08.005_bib37","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.005_bib38","first-page":"728","article-title":"Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.005_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/07853890600925843","article-title":"Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies","volume":"38","author":"Lanas","year":"2006","journal-title":"Ann Med"},{"issue":"7553","key":"10.1016\/j.rdc.2012.08.005_bib40","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.005_bib41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.2008.204","article-title":"Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study","volume":"85","author":"Fosbol","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rdc.2012.08.005_bib42","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.005_bib43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9149(03)00659-3","article-title":"Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"issue":"9549","key":"10.1016\/j.rdc.2012.08.005_bib44","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","article-title":"Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison","volume":"368","author":"Cannon","year":"2006","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.005_bib45","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.005_bib46","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1136\/ard.2011.151191","article-title":"Increased mortality in ankylosing spondylitis is related to disease activity","volume":"70","author":"Bakland","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.005_bib47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.23275","article-title":"Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs","volume":"58","author":"Song","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X12000646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X12000646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:11:39Z","timestamp":1760181099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X12000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0889857X12000646"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2012.08.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Controversies in Spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2012.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}